Evaluation of the Bosphore HBV Quantification Kit: Categorical and Quantitative Agreement with the Aptima HBV Quant Assay for HBV DNA Detection and Quantification
Authors:
- Massimiliano GuerraMGMassimiliano Guerra
- Laura DionisiLDLaura Dionisi
- Claudia ColosimoCCClaudia Colosimo
- Alessandra Mistral De PascaliAPAlessandra Mistral De Pascali
- Martina BrandoliniMBMartina Brandolini
- Ludovica InglettoLILudovica Ingletto
- Maria Sofia MontanariMMMaria Sofia Montanari
- Laura GrumiroLGLaura Grumiro
- Giulia GattiGGGiulia Gatti
- Giorgio DiraniGDGiorgio Dirani
- Silvia ZannoliSZSilvia Zannoli
- Alessandra ScagliariniAlessandra Scagliarini
Open Access
- 1 November 2026
- journal article
- research article
- Published by MDPI AG in Microorganisms
- Vol. 14 (11) , 2489
Abstract
Accurate hepatitis B virus (HBV) DNA quantification is essential for assessing viral replication and monitoring antiviral therapy. This retrospective method-comparison study evaluated the Bosphore HBV Quantification Kit against the Aptima HBV Quant Assay using 130 residual anonymized EDTA-plasma specimens, comprising 110 comparator-positive and 20 comparator-negative samples. Categorical agreement was assessed using positive, negative, and overall percent agreement (PPA, NPA, and OPA), while quantitative agreement was evaluated using a predefined ±0.5 log10 IU/mL criterion, Bland–Altman analysis, Passing–Bablok regression, and Lin’s concordance correlation coefficient (CCC). PPA was 100% (110/110; 95% confidence interval [CI], 96.70–100.00%), NPA was 95.0% (19/20; 95% CI, 75.13–99.87%), and OPA was 99.23% (129/130; 95% CI, 95.79–99.98%). One confirmed qualitative discordance was observed. Overall, 109/110 paired numerical results (99.1%; 95% CI, 95.04–99.98%) were within ±0.5 log10 IU/mL. Bland–Altman analysis showed a mean bias of +0.124 log10 IU/mL, Passing–Bablok regression yielded Y = 0.107 + 1.019X, and Lin’s CCC was 0.991. The Bosphore assay demonstrated high categorical and quantitative agreement with the comparator across the HBV DNA concentration range evaluated, supporting its potential suitability for quantitative HBV DNA testing within the analytical workflow assessed in this study.Keywords
This publication has 34 references indexed in Scilit:
- EASL Clinical Practice Guidelines on the management of hepatitis B virus infectionJournal of Hepatology, 2025
- Hepatitis B virus DNA integration: Implications for diagnostics, therapy, and outcomeJournal of Hepatology, 2024
- Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral loadJournal of Hepatology, 2021
- Performance of the Xpert HBV Viral Load assay versus the Aptima Quant assay for quantifying hepatitis B virus DNADiagnostic Microbiology and Infectious Disease, 2020
- Analytical performance of the Hologic Aptima HBV Quant Assay and the COBAS Ampliprep/COBAS TaqMan HBV test v2.0 for the quantification of HBV DNA in plasma samplesJournal of Clinical Virology, 2018
- How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach?Journal of Hepatology, 2017
- A collaborative study to establish the 3rd WHO International Standard for hepatitis B virus for nucleic acid amplification techniquesBiologicals, 2017
- Clinical Profile, Genotype and Management Updates of Hepatitis B VirusIndian Journal of Virology, 2011
- Monitoring during and after antiviral therapy for hepatitis B #Hepatology, 2009
- Hepatitis B virus structure and biologyMicrobial Pathogenesis, 1989